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Abstract
Background: Bypass of foregut secreted factors promoting insulin resistance is hypothesized to be one of the mechanisms
by which resolution of type 2 diabetes (T2D) follows roux-en-y gastric bypass (GBP) surgery.
Aim: To identify insulin resistance-associated proteins and metabolites which decrease more after GBP than after sleeve
gastrectomy (SG) prior to diabetes remission.
Methods: Fasting plasma from 15 subjects with T2D undergoing GBP or SG was analyzed by proteomic and metabolomic
methods 3 days before and 3 days after surgery. Subjects were matched for age, BMI, metformin therapy and glycemic
control. Insulin resistance was calculated using homeostasis model assessment (HOMA-IR). For proteomics, samples were
depleted of abundant plasma proteins, digested with trypsin and labeled with iTRAQ isobaric tags prior to liquid
chromatography-tandem mass spectrometry analysis. Metabolomic analysis was performed using gas chromatography-
mass spectrometry. The effect of the respective bariatric surgery on identified proteins and metabolites was evaluated using
two-way analysis of variance and appropriate post-hoc tests.
Results: HOMA-IR improved, albeit not significantly, in both groups after surgery. Proteomic analysis yielded seven proteins
which decreased significantly after GBP only, including Fetuin-A and Retinol binding protein 4, both previously linked to
insulin resistance. Significant decrease in Fetuin-A and Retinol binding protein 4 after GBP was confirmed using ELISA and
immunoassay. Metabolomic analysis identified significant decrease of citrate, proline, histidine and decanoic acid specifically
after GBP.
Conclusion: Greater early decrease was seen for Fetuin-A, Retinol binding protein 4, and several metabolites after GBP
compared to SG, preceding significant weight loss. This may contribute to enhanced T2D remission observed following
foregut bypass procedures.
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Introduction
The success of bariatric surgery in obtaining remission of type 2
diabetes (T2D) varies with the type of surgery performed, with
generally higher rates observed after gastric bypass (GBP) or
biliopancreatic diversion, than with purely restrictive operations
such as gastric banding [1,2]. This is not explained by the
difference in overall weight loss achieved by the different
procedures, because weight loss achieved is not significantly
associated with T2D outcome in individuals and there is no
difference in weight loss between patients with remission of T2D
and non-remission between or within bariatric procedures [3].
One of the mechanisms by which procedures involving intestinal
rearrangement such as GBP and biliopancreatic diversion
normalize glycaemia is through greater improvement in insulin
resistance, seen to a lesser extent following non diversionary
surgeries such as sleeve gastrectomy (SG) or gastric banding [4,5].
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To explain the rapid and sustained impact of GBP on
improving glycaemia in patients with type 2 diabetes, two
hypotheses have been proposed: The hindgut hypothesis suggests
that the rapid transit of nutrients to the distal bowel improves
glucose metabolism by stimulating secretion of the incretin
hormone GLP-1 from the ileum and colon L-cells [6]. Indeed,
prandial GLP-1 secretion acts to increase glucose-stimulated
insulin secretion and improves post-prandial glycaemia, however
this does not explain the rapid normalization of fasting glycaemia
seen following GBP [7]. The foregut hypothesis proposes that
nutrient bypass of the upper gut leads to reduction in secretion of
an unidentified gut peptide which promotes insulin resistance
[8,9]. Identification of such a gut peptide could yield insights into
the pathophysiology of obesity associated T2D and new thera-
peutic targets.
Proteomics refers to the identification and/or quantification of
the proteins expressed in a tissue, and is used for both inter- and
intra-individual comparisons of samples [10]. Early proteomic
studies often relied on two-dimensional polyacrylamide gel
electrophoresis [11] while newer proteomic approaches e.g.
isobaric tagging of peptides separated by liquid chromatography
and analyzed using tandem mass spectrometry have been
developed to overcome limitations associated with gel electropho-
resis and allow more rapid and accurate proteomic analysis of
complex proteinaceous samples. New opportunities for discovery
in biofluids have also opened up with the development of selective
depletion strategies for highly abundant proteins which otherwise
tend to dominate the analysis, obstructing the analysis of
biomarkers and other key proteins that are often in low abundance
[11]. Complementing proteomic techniques, metabolomic analysis
offers a highly sensitive means to profile a large number of
metabolites in various metabolic pathways [12] and provides
useful information on activity of metabolic pathways e.g. lipid and
carbohydrate metabolism [13,14].
In this study we combined proteomic and metabolomic
approaches to explore the foregut hypothesis. We aimed to
identify proteins as well as metabolites which were decreased
following GBP (foregut bypassed from nutrient flow), but not after
SG (foregut intact with nutrient flow), with special focus on
molecules already linked to insulin resistance. The post-operative
time point (3 days post-operatively) was carefully chosen in order
to place focus on cause rather than effect. Three days after surgery
the greater expected T2D remission following GBP than SG was
still negligible, hence any significant differences found in the
plasma proteomic and metabolomic profiles were unlikely
resulting from T2D remission. The effect of bypassing the foregut
on secretion of molecules should however be evident shortly after
GBP. By performing within-patient comparisons of fasting plasma
protein and metabolite profiles before and soon after either GBP
or SG when post–surgical caloric intake and physical activity was
equivalent and very little weight loss had occurred, we also
avoided confounding effects of weight loss and differences in
caloric intake.
Materials and Methods
A non-randomised, matched, prospective controlled interven-
tion trial that compared the acute effect of GBP to SG, compared
with matched caloric intake, on glycemia among obese patients
with type 2 diabetes has been previously described with its
inclusion and exclusion criteria [15]. Briefly, from 1 August 2010
to 31 March 2012, 21 obese patients with type 2 diabetes treated
with oral glucose lowering therapies (but not incretin hormone
therapies) were recruited by contacting patients on the bariatric
surgery waiting lists, 10 who were scheduled for SG and 11 who
were scheduled for GBP. A total of 7 patients who had SG and 8
who had GBP, all treated with metformin monotherapy at
baseline, were eligible for inclusion in this pilot proteomic and
metabolomic study. Baseline and follow up assessments were
conducted in the patients’ homes at 3 pre- and post-operative days.
The protocol, allocation and supporting TREND checklist for this
study are available as supporting information (Checklist S1 and
Protocol S1), and Figureoˆ 1 for the allocation flow chart. All
patients were prescribed a hypocaloric diet with three servings of
Optifast (152 Calories) per day during the three weeks prior to
surgery and were instructed to fast from midnight the night before
surgery. Patients received general anaesthesia with atracurium and
propofol or equivalent agents for both laparoscopic surgeries. The
GBP consisted of a 100 cm antecolic Roux-limb with hand-sewn
pouch-jejunostomy, a 60 cm bilio-pancreatic limb and a hand
sewn small bowel anastomosis. The SG was performed by a
longitudinal resection of the stomach against a 32 French bougie
from just lateral to the angle to His to 2 cm proximal to the
pylorus.
Post-operative IV fluids with Plasmalyte were administered until
oral fluid intake was 1 litre per day (approximately 48 hours).
Routine medications given for the first 48 hours included
analgesia as required (paracetamol, tramadol and fentanyl), anti-
emetics (ondansetron, cyclizine and metoclopramide), and subcu-
taneous heparin as prophylaxis for venous thrombo-embolism.
Metformin therapy was stopped from the day of surgery until the
end of the study period. Standard post-operative oral intake
instructions were as follows: Day 1, sips of water; Day 2-4, free oral
fluids with clear soups, low fat smoothies or Optifast.
Approximately 3 days before surgery, and again 3 days after
surgery, in both cases following fasting for at least 10 hours, blood
samples were collected into EDTA tubes and centrifuged following
Figure 1. 2010 CONSORT flow diagram for the study.
doi:10.1371/journal.pone.0096489.g001
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routine procedures to yield plasma samples which were stored at
280uC until analysis.
Ethics statement
This prospective study was approved by the Northern X
Regional Ethics Committee, New Zealand and was registered with
the Australian New Zealand Clinical Trials Registry
(ACTRN12609000679280). Informed, written consent was ob-
tained from all patients.
Metabolic parameters
Serum insulin and glucose were quantified using the Human
Metabolic Hormone Panel (Milliplex, Millipore) and Hitachi 902
auto-analyzer (Hitachi High Technologies Corporation), respec-
tively. HOMA-IR was calculated as (fasting insulin in mU/ml x
fasting glucose in mmol/L)/22.5.
Proteomic procedures
Plasma samples were subjected to immunodepletion of 20
highly abundant serum proteins (albumin, immunoglobulins (IgG,
IgM, IgD), transferrin, fibrinogen, a-1-antitrypsin, a-2-antitrypsin,
complements C3, C4, C1q, haptoglobin, apolipoproteins (A1, A2,
B), acid-1-glycoprotein, ceruloplasmin, prealbumin, plasminogen)
using a ProteoPrep 20 plasma immunodepletion centrifugal device
(Sigma Aldrich, St Louis, MO, USA,) according to the manufac-
turer’s instructions. Depleted samples were stored at 280uC until
further processing. Sample volumes containing 40 mg total protein
were reduced at 55uC for 15 minutes using 10 mM dithiothreitol,
alkylated with 50 mM iodoacetamide (Sigma) at room tempera-
ture for 45 minutes in the dark and then digested at 40uC for
30 minutes with 2 mg of sequencing grade trypsin (Promega,
Madison, WI, USA) in a chilled microwave (CEM Corporation,
Matthews, NC, USA). Digests were cleaned up on 10 mg Oasis
HLB SPE cartridges (Waters, Milford, MA, USA), eluted with
300 ml of 60% acetonitrile, dried in a vacuum centrifuge (Thermo
Savant, Holbrook, NY, USA) and reconstituted with 20 ml of
iTRAQ dissolution buffer (0.5 M triethylammonium bicarbonate
at pH 8.5; Applied Biosystems, Foster City, CA, USA). Two
samples from each subject (pre- and post- surgery) were derivatised
with one of eight iTRAQ labels and combined in groups of eight.
Pooled samples were separated by multidimensional liquid
chromatography using a strong cation exchange column, followed
by a reversed phase column (150 mm6300 um Zorbax SB 300A
C-18 column, Agilent Technologies, Santa Clara, CA, USA). The
column effluent was analyzed on a QSTAR-XL hybrid mass
spectrometer (Applied Biosystems). A TOF-MS scan was made
from m/z 300-1600 and the three most intense multiply-charged
precursors isolated for fragmentation, with MS/MS spectra
recorded from m/z 75-1600.
The patient samples were first analyzed in groups of eight as
described above across four liquid chromatography-tandem mass
spectrometry (LC-MS/MS) runs; an additional LC-MS/MS run
containing selected samples from all four individual runs was then
conducted to enable comparisons between runs.
The LC-MS/MS outputs were used to search the human IPI
database (Version 3.87) using ProteinPilot software version 4.0
(Applied Biosystems) and protein matches with scores above the
1% false discovery rate threshold for each run were accepted for
quantitative analysis. In cases where the software identified an
unnamed or putative protein from the database, the amino acid
sequence of the protein was used to conduct a BLAST search
(available online at http://blast.ncbi.nlm.nih.gov/Blast.cgi) to gain
a more meaningful identifier.
The ProteinPilot peptide summaries were used to manually
calculate the abundance of each protein in each sample relative to
a pre-GBP sample included in the same run as previously
described [16]. By comparing in the additional run all pre-GBP
samples that were used as reference samples within the previous
runs, results obtained from separate LC-MS/MS runs could be
scaled and effectively used to compare all samples across all runs.
Finally, average ratios calculated in log space for each group were
converted to linear space for presentation. Confidence intervals
were calculated by converting to linear space the average ratios (ln)
6 SEM (ln). Data files containing the complete proteomic output
are available from the authors upon request.
Proteins of interest were validated using immunoassay or
ELISA. Retinol Binding Protein 4 (RBP4) was measured as per
manufacturer’s protocol using the Human RBP4 Immunoassay
Kit (AIS antibody and Immunoassay Services, Hong Kong).
Fetuin-A were measured by a sandwich ELISA (BioVendor
Laboratory Medicine, Brno, Czech Republic).
Metabolomics procedures
For each sample, a 300 mL aliquot of plasma was spiked with
20 mL of internal standard (10 mM d4-alanine; 2,3,3,3-d4-dl-
alanine, 98 atom % D; Sigma-Aldrich), then lyophilised overnight
before being extracted first with 500 mL of 50% methanol, then
with 500 mL of 80% methanol. Extracted supernatants were
pooled and freeze-dried. Dried samples were chemically deriva-
tised by methyl chloroformate and analyzed by Gas Chromatog-
raphy-Mass spectrometry (Agilent 7890A coupled with a 5975
inert Mass Spectrometry Detector). Chromatograms were pro-
cessed using an in-house metabolite library and a custom-made R-
software package, with manual checking and correction of
information (GC-MS peak intensities). Metabolomic data for each
sample were normalized using the internal standard prior to
calculation of relative abundances of the separate metabolites in
the four different groups.
Statistical analysis
All statistical calculations were performed using GraphPad
Prism version 6.00 (GraphPad Software, La Jolla California USA).
Statistical significance of the effect of bariatric surgery on fasting
glucose, fasting insulin and HOMA-IR was assessed using
repeated measures, mixed model two-way ANOVA, pairing each
post-operative sample with the pre-operative sample from the
same patient.
Statistical analysis of the proteomic data was done after
conversion of all ratios to their natural logs, as customary for
iTRAQ data. The separate effect of surgery (post- versus pre-) as
well as surgery group (GBP versus SG) were calculated for all
identified proteins using repeated measures, mixed model two-way
ANOVA paired as above. All proteins showing significant effect of
bariatric surgery (p,0.05), were further evaluated using Sidak’s
multiple comparisons post-hoc test to test the specific effect of GBP
and SG on protein levels.
The results of the immunoassay and ELISA validations were
tested using two-tailed one sample t tests.
For metabolomic data, the separate effects of bariatric surgery
as well as surgery type were calculated for all identified metabolites
using repeated measures, mixed model two-way ANOVA.
Metabolites showing significant effect of bariatric surgery (p,
0.05) were further evaluated using Sidak’s multiple comparisons
post-hoc test to test the specific effect of GBP and SG on
metabolite levels.
Correlation between selected proteins/metabolites and
HOMA-IR was evaluated using Spearman correlations.
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Results
Clinical characteristics
Fifteen obese subjects participating in a prospective bariatric
surgery study [15] (8 scheduled for GBP, 7 for SG) were selected
for this study based on similarity of baseline characteristics
(Table 1). All patients were treated with metformin for T2D prior
to surgery only. Despite cessation of metformin therapy post-
operatively, mean fasting glucose and insulin levels, as well as
insulin resistance (HOMA-IR) improved after both GBP and SG,
although the differences did not reach statistical significance
(Table 1).
Proteomic analysis
Of a total of 85 proteins identified with sufficient iTRAQ label
and in three or more individuals per surgery group (Fig. 2), two-
way ANOVA analysis showed significant effect of bariatric surgery
for 32 proteins when time (before vs. after surgery) was plotted
against surgery type (GBP vs SG). Of these, 23 proteins were
significantly different also in post hoc tests, where the effects of the
two surgery types were analyzed separately (Table 2). Summary
statistics for all 85 identified proteins are available in Table S1.
Specifically, six proteins were significantly lower and four
significantly higher after both surgery types, four proteins
increased and one decreased after SG only while only one protein
increased after GBP. Seven proteins were significantly lower after
GBP only and hence matched the main aim of the study. Of these,
two (RBP4 and Fetuin-A) were previously reported in the context
of insulin resistance. The significant decrease in RBP4 (decreased
to 72% after GBP, p,0.01) and Fetuin-A (decreased to 75% after
GBP, p,0.05) as demonstrated by the iTRAQ proteomic study is
detailed in Figure 3. Validation analysis by immunoassay and
ELISA confirmed significant decrease of RBP4 (251.566.1%, p,
0.0001) and Fetuin-A (227.063.5%, p= 0.0001) on day 3 after
GBP (Fig. 4); consistent with the iTRAQ results. As shown in
Table 3, the measured levels of both RBP4 and Fetuin-A showed
significant correlation with HOMA-IR.
Metabolomic analysis
A total of 45 metabolites were detected, of which 19 were fatty
acids and 20 were amino acids or amino acid derivatives. Eight
metabolites showed significant (p,0.05) impact of bariatric
surgery in the two-way ANOVA; post hoc analysis detected
significant effect of one or both specific surgery types for seven of
these (Table 4). Figure 5 shows significantly affected and other
relevant metabolites in their implicated pathways. Summary
statistics for all 45 detected metabolites are available in Table S2.
Discussion
We hypothesized that key species promoting insulin resistance
(proteins or their downstream metabolic targets) would be
decreased following GBP, where the foregut is bypassed from
nutrient flow, but not after SG, where the foregut remains intact to
nutrient flow. To identify such causal metabolic factors, we chose
to study subjects shortly after both types of surgery, specifically
before significant weight loss had occurred and before differences
in remission of diabetes between the two types of surgery were
evident.
Table 1. Subject characteristics and effect of surgeries on fasting glucose, fasting insulin and HOMA-IR.
GBP (n=8) SG (n=7)
Sex Females: 8 Females: 6
Males: 0 Males: 1
Age (yrs) 41.063.1 46.862.9
Ethnicity 5 NZE 6 NZE
2 PI 1 PI
1 Asian
Duration diabetes (yrs) 3.760.7 3.160.6
BMI (kg/m2) 42.164.0 42.365.9
HbA1c (%) 7.260.2 7.860.7
(mmol/mol) 54.862.5 61.967.8
Duration of surgery (hours) 2.6060.08 2.1460.01
Baseline Day 3 post surgery Baseline Day 3 post surgery
Fasting glucose (mmol/L) 6.960.7 5.960.5 7.060.7 6.160.6
p (pre Vs post bariatric surgery): 0.06
p (SG Vs GBP): 0.82
Fasting insulin (mIU/mL) 17.566.9 10.862.7 20.665.6 16.966.0
p (pre Vs post bariatric surgery): 0.15
p (SG Vs GBP): 0.53
Log HOMA-IR 1.0760.45 0.7560.32 1.6460.25 1.2660.31
p (pre Vs post bariatric surgery): 0.18
p (SG Vs GBP): 0.23
Data are shown as mean 6 S.E.M.; p values are derived from Mixed Model Repeated Measures Two-Way ANOVA. Abbreviations: NZE, NZ European; PI, Pacific Islander;
HOMA-IR, insulin resistance calculated by homeostatic model assessment.
doi:10.1371/journal.pone.0096489.t001
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Amongst other findings, our proteomic analysis showed a
significant decrease in two proteins involved in insulin resistance,
RBP4 and Fetuin-A, [17,18], three days after GBP but not SG.
Notably, although insulin resistance had not improved significantly
three days after bariatric surgery, the statistically significant
correlations between the levels of RBP4 and Fetuin-A with
HOMA-IR support a direct relationship between lower levels of
these proteins and improved insulin resistance in our dataset.
RBP4 is a vitamin A (retinol) transport protein secreted by
hepatocytes and adipocytes into the bloodstream. This protein
carries retinol to peripheral tissues where it is converted into
ligands for nuclear hormone receptors and regulates gene
transcription. In recent years, RBP4 has been proposed to be a
cardiometabolic risk factor associated with T2D, obesity and
hyperlipidaemia [19] and it appears to induce insulin resistance in
skeletal muscle, liver and adipose tissue in vitro [20]. The
regulation of RBP-4 is unclear, however RBPR2 was recently
identified as a high affinity RBP4 receptor expressed primarily in
liver and small intestine and induced in adipocytes of obese mice
[21]. Studies show that RBP4 is decreased with hypocaloric diet
[22] as well as weight loss achieved by lifestyle [23] or weight loss
achieved by SG bariatric surgery [12,24].
Fetuin-A is produced in the liver and has a role in the inhibition
of insulin-receptor tyrosine kinase, which attenuates insulin
signalling and triggers insulin resistance [25,26] and also down-
regulates adiponectin, a known insulin sensitizer secreted by
adipose tissue [27]. Fetuin-A has recently been shown to be an
endogenous ligand for Toll-like receptor 4 (TLR4) through which
it has a critical role in stimulating adipose tissue inflammation
resulting in insulin resistance [28]. The regulation of Fetuin-A is
thought to be through pro-inflammatory cytokines [29,30]. Studies
suggest that those with high Fetuin-A levels have increased risk of
myocardial infarction [31], stroke [32], and incident diabetes [17].
Fetuin-A levels have also been reported to decrease after weight
Figure 2. Heat map showing patient specific changes of all detected proteins. Each protein is represented on an individual row with data
from each patient stacked in columns (GBP1 to GBP8 for GBP, SG1-SG7 for SG). Intensity of color corresponds to the degree of change from red
(decrease) to green (increase) after surgery.
doi:10.1371/journal.pone.0096489.g002
Figure 3. Proteomic results for Fetuin-A and RBP4. Relative
abundance pre and post GBP and SG for Fetuin-A (A), and RBP4 (B) as
per iTRAQ proteomic study, showing significant decrease after GBP but
not after SG for both proteins. Abbreviations: *, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0096489.g003
Figure 4. Validation of proteomic results for Fetuin-A and
RBP4. Panel A: Fetuin-A levels were found by ELISA to decrease to
some extent after both surgery types, however a more dramatic
decrease was found after GBP. Panel B: significantly lower levels of RBP4
were detected by immunoassay after GBP only. Abbreviations: *, p,
0.05; ***, p,0.001; ****, p,0.0001.
doi:10.1371/journal.pone.0096489.g004
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Table 2. Proteins displaying post-operative changes in relative abundance (3 days after GBP and/or SG compared to 3 days prior
to surgery) according to the proteomic study.
Protein name (Accession No) pre GBP/pre GBP post GBP/pre GBP pre SG/pre GBP post SG/pre GBP
Significant change after GBP only
Isoform 2 of Inter-alpha-trypsin inhibitor heavy chain H3 (IPI00876950.1) 1.00 1.33 ** 1.15 1.29 (n.s.)
(0.88–1.14) (1.16–1.54) (1.00–1.32) (1.09–1.53)
RBP4 (retinol-binding protein 4) (IPI00844536.2) 1.00 0.72 ** 1.02 0.90 (n.s.)
(0.87 –1.14) (0.63–0.83) (0.85–1.22) (0.75–1.09)
Alpha-2-HS-glycoprotein ( = Fetuin-A) (IPI00953689.1) 1.00 0.75 * 0.96 0.87 (n.s.)
(0.91–1.10) (0.67–0.85) (0.82–1.13) (0.75–1.00)
Coagulation factor X (IPI00019576.1) 1.00 0.83 * 1.07 0.98 (n.s.)
(0.87–1.14) (0.71–0.96) (0.87–1.32) (0.78–1.23)
Coagulation factor XII (IPI00019581.2) 1.00 0.88 * 0.96 0.87 (n.s.)
(0.87–1.15) (0.75–1.03) (0.84–1.10) (0.76–1.00)
Heparin cofactor 2 (IPI00879573.1) 1.00 0.74 *** 1.18 1.03 (n.s.)
(0.90–1.11) (0.67–0.82) (1.04–1.35) (0.89–1.19)
Inter-alpha-trypsin inhibitor heavy chain 2 (IPI00645038.1) 1.00 0.81 ** 1.05 0.97(n.s.)
(0.94–1.06) (0.74–0.89) (1.01–1.08) (0.91–1.04)
Tetranectin (IPI00009028.2) 1.00 0.80 * 0.90 0.82 (n.s.)
(0.91–1.10) (0.75–0.85) (0.80–1.02) (0.76–0.89)
Significant change after SG only
Complement C5 (IPI00032291.2) 1.00 1.07 (n.s.) 1.00 1.21 *
(0.92–1.08) (0.99–1.15) (0.91–1.09) (1.11–1.31)
Complement component C8 alpha chain (IPI00011252.1) 1.00 1.06 (n.s.) 1.03 1.24 *
(0.91–1.10) (0.97–1.16) (0.94–1.12) (1.11–1.39)
CFB cDNA FLJ55673, (highly similar to Complement factor B)
(IPI00019591.2)
1.00 1.04 (n.s.) 0.98 1.17 *
(0.93–1.08) (0.97–1.12) (0.91–1.07) (1.07–1.29)
Isoform 1 of Inter-alpha-trypsin inhibitor heavy chain H4 (IPI00896419.3) 1.00 1.04 (n.s.) 0.97 1.14 **
(0.93–1.07) (0.98–1.10) (0.90–1.04) (1.08–1.20)
N-acetylmuramoyl-L-alanine amidase (IPI00163207.1) 1.00 0.89 (n.s.) 1.09 0.85 **
(0.88–1.14) (0.77–1.04) (0.96–1.23) (0.73–0.98)
Significant change after both surgery types
Isoform 1 of C-reactive protein (IPI00022389.1) 1.00 7.79 **** 0.78 4.32 ****
(0.82–1.22) (6.07–9.99) (0.61–1.01) (3.47–5.37)
SERPINA3 (highly similar to alpha-1-antichymotrypsin) (IPI01025667.1) 1.00 1.61 **** 0.92 1.46 ****
(0.76–1.31) (1.24–2.10) (0.68–1.24) (1.04–2.06)
Complement component C9 (IPI00022395.1) 1.00 1.43 *** 0.90 1.42 ***
(0.92–1.09) (1.34–1.51) (0.80–1.00) (1.36–1.49)
Leucine-rich alpha-2-glycoprotein (IPI00022417.4) 1.00 1.70 *** 0.80 1.23 **
(0.91–1.10) (1.51–1.91) (0.70–0.91) (1.12–1.34)
Apolipoprotein A-IV (IPI00304273.2) 1.00 0.40 **** 0.85 0.49 ***
(0.86–1.16) (0.34–0.46) (0.78–0.93) (0.42–0.55)
Insulin-like growth factor-binding protein complex acid labile
subunit (IPI00925635.1)
1.00 0.81** 0.81 0.63 **
(0.95–1.05) (0.75–0.86) (0.76–0.87) (0.57–0.69)
Beta-Ala-His dipeptidase (Carnosine dipeptidase 1) (IPI00064667.5) 1.00 0.75 ** 1.11 0.74 ***
(0.91–1.10) (0.67–0.84) (0.98–1.25) (0.65–0.84)
Kallistatin (IPI00328609.3) 1.00 0.70 *** 1.11 0.90 *
(0.95–1.05) (0.66–0.75) (1.01–1.22) (0.85–0.95)
Gelsolin (IPI00026314.1) 1.00 0.74 *** 0.89 0.69 **
(0.94–1.07) (0.68–0.80) (0.81–0.98) (0.68–0.70)
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loss achieved by lifestyle [33] and after GBP [34].
The greater decrease of both Fetuin-A and RBP4 seen after
GBP than after SG is consistent with an impact of foregut
exclusion on reducing these proteins. In the case of RBP4, this
may be because diversion of nutrient absorption past the
duodenum resulted in reduced foregut absorption of retinol and
expression of RBRP2 [21]. Alternatively, altered gut microbiota,
which has been reported to occur after both types of surgery
[35,36,37], may influence the levels of these plasma proteins. For
example, distinct gut microbiota functional changes after GBP
may produce less circulating endotoxin levels and thereby incite
lower levels of Fetuin-A [37]. Further studies are required to
document the functional evolution of gut microbiota after foregut
excluding GBP compared to restrictive types of bariatric surgery
such as SG in order to test these hypotheses.
Our metabolomic analysis highlighted several metabolites
which responded differently to the two types of bariatric surgery.
Specifically after GBP, we detected significantly lower levels of the
glucogenic amino acids histidine and proline, as well as of citrate
and decanoic acid. This response is consistent with improved
metabolic status based on several points. Enhanced post-prandial
disposal of amino acids and more complete beta-oxidation of fatty
acids has been reported following GBP compared with caloric
restriction [38]. Elevated free fatty acids are well known to be
associated with insulin resistance [39] and decreased decanoic acid
after GBP may be a result of a greater uptake of long chain fatty
acid into adipocytes [40]. Elevated histidine [41,42] and citrate
[43,44,45,46] levels have been linked with insulin resistance and
T2D. Although we did not find any correlation between these four
metabolites and insulin sensitivity at this early stage, it is possible
they may be predictive of future improvements.
Conversely, after SG we detected marked elevation of the
branched-chain amino acid catabolite 3-methyl-2-oxo-pentanoic
acid, accompanied by a non-significant tendency towards
increased levels of all branched-chain amino acids. The latter is
a well-known phenomenon in insulin resistance [47]. Also
substantially elevated following SG was 2-hydroxybutyrate, which
has been proposed as a plasma biomarker for early stages of
diabetes [48] and insulin resistance [49].
Together, the differential early changes in the above metabolites
following GBP and SG suggest a more favourable metabolic
profile associated with greater insulin sensitivity early after GBP
compared with SG. Since both surgery groups were of similar
obesity and diabetes status as well as similar in terms of reduced
caloric intake at the post-operative time-point, these differences
are likely directly linked to the types of bariatric surgery
performed.
This study has two major limitations. Firstly, it is limited by
small sample size. The subjects were however well matched for
baseline clinical characteristics before two relatively similar
laparoscopic bariatric surgical procedures with well-matched
post-operative protocols for analgesia, fluid replacement and
caloric intake. Secondly, the immunodepletion method used in the
proteomic analysis improved detection of moderately abundant
proteins but had limited ability to prime the samples for detection
of proteins of very low abundance in plasma. Depletion techniques
targeting a larger number of proteins [50] would allow a more
comprehensive analysis in the search for additional novel
biomarkers of insulin resistance. Nonetheless, our proteomic study
identified significant decreases in RBP4 and Fetuin-A concentra-
tions after GBP but not after SG, which was confirmed using other
analytical methods. The metabolomic analysis was also limited to
a relatively moderate number of metabolites and future investi-
gations will benefit from the use of more powerful equipment.
Although we were unable to obtain a clear connection between
our proteomic and metabolomics findings, by using these two
complementary analytical approaches, we managed to identify a
number of potentially important changes in key metabolic
pathways as well as proteins with known or putative roles in the
development of insulin resistance.
In summary, our findings suggest greater lowering of multiple
proteins including RBP4, Fetuin-A as well as several metabolites
associated with insulin resistance following GBP compared with
SG prior to diabetes remission.
Table 2. Cont.
Protein name (Accession No) pre GBP/pre GBP post GBP/pre GBP pre SG/pre GBP post SG/pre GBP
Afamin (IPI00019943.1) 1.00 0.76 *** 1.05 0.80 **
(0.94–1.07) (0.70–0.82) (0.97–1.14) (0.74–0.88)
All listed proteins displayed significant (p,0.05) effect of surgery (SG and GBP) as tested by two-way analysis of variance. IPI numbers in brackets refers to accession
numbers in the human IPI database; asterisks following ratios denote significant effect of the indicated surgery type according to post-hoc test;
*, p,0.05;
**, p,0.01;
***, p,0.001;
****, p,0.0001; n.s., not significant. Values in brackets refer to confidence intervals.
doi:10.1371/journal.pone.0096489.t002
Table 3. Assessment of correlation between selected proteins and metabolites (showing greater decrease after GBP than SG) with
insulin resistance (estimated by HOMA-IR).
Fetuin-A RBP4 Proline Citrate Histidine Decanoic acid
HOMA-IR 0.36 0.48 0.10 0.06 –0.04 –0.07
p (,0.05)* (0.006)** (0.61) (0.74) (0.85) (0.72)
The values shown are Spearman rank correlation coefficients with two-tailed p values for significance of correlation in brackets. Asterisks highlights significant
correlations (*, p,0.05; **, p,0.01).
doi:10.1371/journal.pone.0096489.t003
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Figure 5. Schematic of implicated metabolic pathways based on metabolomics results (selected metabolites only). Metabolites are
inscribed in color coded ellipses with the effect of GBP in left half and effect of SG in right half. Color code: blue, significantly lower; orange,
significantly higher; white, no significant effect of bariatric surgery; diagonal stripes, significant effect of surgery but not significant in post-hoc test.
Grey highlights an undetected metabolite.
doi:10.1371/journal.pone.0096489.g005
Table 4. Metabolites showing significant effect (p,0.05) of bariatric surgery in a Repeated Measures Mixed Model Two-Way
ANOVA.
Metabolite Pre-GBP Post-GBP Pre-SG Post-SG Effect of surgery (p)
Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM
Alanine 1.0060.09 0.52±0.04* 1.2760.19 0.68±0.06** 0.0001
Proline 1.0060.12 0.56±0.09* 1.0060.18 0.7160.11 0.0046
Histidine 1.0060.12 0.72±0.07* 0.7860.10 0.6860.07 0.0073
Threonine 1.0060.16 0.8460.10 0.8060.14 0.7860.08 0.0452
Citric acid 1.0060.10 0.76±0.07* 1.0060.07 0.8860.07 0.0095
Decanoic acid 1.0060.12 0.67±0.08* 0.8660.07 0.7760.07 0.0232
2-Hydroxybutyric acid 1.0060.14 1.1660.17 0.9760.12 2.01±0.39* 0.0359
3-Methyl-2-oxopentanoic acid 1.0060.11 0.9360.14 0.8160.12 1.57±0.24** 0.0428
Values given are scaled to mean pre-GBP to enable comparison between all groups. Asterisks denote significant difference compared to baseline for the specific surgery
type (Sidak’s multiple comparisons test);
*, p,0.05;
**, p,0.01.
doi:10.1371/journal.pone.0096489.t004
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confidence and iTRAQ label in at least 3 within-patient comparisons
as well as the final LC-MS/MS run combining samples from all
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